Multiple Myeloma
Track treatment pathways, prescriber behavior and market dynamics in Multiple Myeloma, powered by real-world data, not assumptions.
Why Therapy Intelligence™
The intelligence your teams actually need
Leveraging real-world patient data, our Therapy Intelligence™ solution goes beyond syndicated studies to deliver
fast, robust, multi-country insights, whether used standalone or integrated with custom methodologies.
Ready in days
Data already collected. Access study extracts immediately, full data within days of your request.
Physician-led study design
Every study is co-designed with leading physicians in the therapeutic area. Rigorous methodology, clinically grounded.
Fully customizable analysis
The analysis is yours to shape. Tell us what questions matter to your strategy and we tailor the outputs accordingly.
Trusted by Top 15 Global Pharma Companies
Study Scope
The questions that matter in Multiple Myeloma
Our Multiple Myeloma Therapy Intelligence covers the full patient journey, from diagnosis through later lines of therapy, including treatment sequencing, prescriber decision drivers, patient-reported burden and quality of life. Modules can be tailored to your research questions.
1+
HCP interviewed
1
Countries covered
1k+
PRFs
Which patients are actually receiving innovative therapies like CAR-T and bispecifics and which are being missed?
How are treatment sequences evolving as new therapies move into earlier lines?
What happens to patients after CAR-T or bispecific antibody exposure?
What really drives physicians' treatment decisions, beyond published guidelines?
Where are the practical barriers slowing adoption of innovative regimens?
How is the competitive landscape shifting across lines of therapy?
Clinical Truth to Business Impact
From the lab to the boardroom
Growth Lever
Message
Application
Identify growth opportunities
Untapped patient segments, under-treated eligible pools and white-space opportunities
e.g. Under-treated pools in later lines of therapy
Refine your positioning
See where the brand wins, where it stalls and how the competitive frame should evolve
e.g. Positioning versus emerging cell/gene therapies
Activate the right HCPs
Identify over- and under-performing physicians and unlock adoption opportunities
e.g. Hematologist segments slower to adopt new regimens
Anticipate market evolution
Track launches, sequence changes, access shifts and new behaviors earlier
e.g. Shifting treatment sequencing as new therapies launch
Let's Talk
Paul Taylor
Strategic Partnership Director
Manuel Guzman Martin
Vice President Commercial Global
Mélanie Marrot, PhD
Vice President Commercial France
